OXOID MANUAL PRELIMS 16/6/06 12:18 Pm Page 1

Total Page:16

File Type:pdf, Size:1020Kb

OXOID MANUAL PRELIMS 16/6/06 12:18 Pm Page 1 OXOID MANUAL PRELIMS 16/6/06 12:18 pm Page 1 The OXOID MANUAL 9th Edition 2006 Compiled by E. Y. Bridson (substantially revised) (former Technical Director of Oxoid) Price: £50 OXOID MANUAL PRELIMS 16/6/06 12:18 pm Page 2 The OXOID MANUAL 9th Edition 2006 Compiled by E. Y. Bridson (substantially revised) (former Technical Director of Oxoid) 9th Edition 2006 Published by OXOID Limited, Wade Road, Basingstoke, Hampshire RG24 8PW, England Telephone National: 01256 841144 International: +44 1256 841144 Email: [email protected] Facsimile National: 01256 463388 International: +44 1256 463388 Website http://www.oxoid.com OXOID SUBSIDIARIES AROUND THE WORLD AUSTRALIA DENMARK NEW ZEALAND Oxoid Australia Pty Ltd Oxoid A/S Oxoid NZ Ltd 20 Dalgleish Street Lunikvej 28 3 Atlas Place Thebarton, Adelaide DK-2670 Greve, Denmark Mairangi Bay South Australia 5031, Australia Tel: 45 44 97 97 35 Auckland 1333, New Zealand Tel: 618 8238 9000 or Fax: 45 44 97 97 45 Tel: 00 64 9 478 0522 Tel: 1 800 331163 Toll Free Email: [email protected] NORWAY Fax: 618 8238 9060 or FRANCE Oxoid AS Fax: 1 800 007054 Toll Free Oxoid s.a. Nils Hansen vei 2, 3 etg Email: [email protected] 6 Route de Paisy BP13 0667 Oslo BELGIUM 69571 Dardilly Cedex, France PB 6490 Etterstad, 0606 Oxoid N.V./S.A. Tel: 33 4 72 52 33 70 Oslo, Norway Industriepark, 4E Fax: 33 4 78 66 03 76 Tel: 47 23 03 9690 B-9031 Drongen, Belgium Email: [email protected] Fax: 47 23 09 96 99 Tel: 32 9 2811220 Email: [email protected] GERMANY Fax: 32 9 2811223 Oxoid GmbH SPAIN Email: [email protected] Postfach 10 07 53 Oxoid S.A. BRAZIL D-46467 Via de los Poblados 10 Oxoid Brasil Ltda Wesel, Germany Nave 3-13 rua Arizona 1349 Tel: 49 281 1520 Madrid 28033, Spain 8° andar – Conjunto 01 Fax: 49 281 1521 Tel: 34 91 382 2021 Brooklin Novo Fax: 34 91 763 7662 IRELAND Sao Paulo – SP Oxoid Ireland SWEDEN 04567-003, Brasil c/o Fannin Healthcare Ltd Oxoid AB Tel: 00 55 11 5505 0014 Blackthorn Road Sjöängsvägen 7 Fax: 00 55 11 5505 6010 Sandyford Industrial Estate S-192 72 Sollentuna, Sweden Email: [email protected] Foxrock, Dublin 16 Tel: 46 8 626 6050 CANADA Tel: 353 1 2944500 Fax: 46 8 626 6059 Oxoid Company Fax: 353 1 2953818 Email: [email protected] Suite 100 Email: [email protected] SWITZERLAND 1926 Merivale Road ITALY Oxoid AG Nepean Oxoid S.p.A. Reichensteinerstrasse 14 Ontario K2G 1E8, Canada Via Montenero 180 Postfach CH-4002 Basel, Switzerland Tel: 613 226 1318 or 20024 Garbagnate Mil.sc (MI), Italy Tel: 41 61 271 6660 Tel: 800 267 6391 Toll Free Tel: 39 02 994 721 Fax: 41 61 271 6608 Fax: 613 226 3728 Fax: 39 02 995 8260 Email: [email protected] USA Email: [email protected] Remel Inc NETHERLANDS 12076 Santa Fe Drive Head Office: Wade Road, Basingstoke, Oxoid B.V. PO Box 14428 Hampshire RG24 8PW, England Pieter Goedkoopweg 38 Lenexa 2031 EL Haarlem KS 66215, USA © Copyright 1998 by Oxoid Ltd Postbus 490 Tel: 800 255 6730 All rights reserved. No part of this publication 2000 AL Haarlem, Holland Fax: 800 621 8251 may be reproduced, stored in a retrieval Tel: 31 2353 19173 Email: [email protected] system, or transmitted, in any form or by any Fax: 31 2353 10543 means, electronic, mechanical, photocopying, Email: [email protected] recording or otherwise, without the prior written permission of the publisher. Printed in the United Kingdom OXOID MANUAL PRELIMS 16/6/06 12:18 pm Page 3 CONTENTS 1 INTRODUCTION (History of Company) The Oxoid Quality Policy Storage of Oxoid Microbiological Products Precautions in Microbiology 2 CULTURE MEDIA 3 SUPPLEMENTARY REAGENTS 4 LABORATORY PREPARATIONS 5 ANAEROBIC SYSTEMS 6 BLOOD CULTURE 7 ANTIMICROBIAL SUSCEPTIBILITY TESTING 8 BIOCHEMICAL IDENTIFICATION 9 RAPID FOOD TESTS 10 DIAGNOSTIC REAGENTS 11 CULTI-LOOPS AND QUANTI-CULT 12 PRODUCT INDEX OXOID MANUAL PRELIMS 16/6/06 12:18 pm Page 4 LEFT BLANK OXOID MANUAL SECTION 1 16/6/06 12:02 pm Page 1 1 INTRODUCTION OXOID MANUAL SECTION 1 16/6/06 12:02 pm Page 2 2006 OXOID MANUAL SECTION 1 16/6/06 12:02 pm Page 1 Introduction INTRODUCTION The origins of OXOID Ltd go back to the beginnings of the science of microbiology. Justus von Liebig (a famous chemist who clashed with Louis Pasteur about the microbiological cause of fermentation) had long been concerned about malnutrition in the poor of Europe. In 1860 he devised a concentrated meat extract which could be stored at room temperature without risk of spoilage. He called it “Extractum carnis’’ and he hoped it could be made available to everyone. This hope could not be achieved in Europe because of the high price of meat. However, in 1861, George Christian Giebert, a Belgian engineer working in Uruguay, read of this work and of Liebig’s promise to help anyone who could produce the Extract to the same high standards. Both men knew that in South America, cattle were being slaughtered in thousands, solely for their hides and fat, the meat being abandoned to rot. Giebert visited Liebig in his Munich factory, learned the process and raised money in Antwerp to create a meat extract factory at Fray Bentos in Uruguay. Liebig approved of Giebert’s product and allowed it to be called Liebig Extract of Meat. By 1865, production was so successful that the company was running out of money. This problem was solved when the Liebig Extract of Meat Company was formed and registered in London that same year. Both scientist and engineer had succeeded in their tasks. When Liebig died in 1873, he knew that his excellent extract was available to all in Europe. When Giebert died, a year later, he knew that he had established a sound industrial basis for the production of high quality products. Later more factories were established in South America, with surrounding ranches to breed cattle. After Liebig’s death, it was no longer possible to protect the great man’s name on the bottle of Extract. Inferior Liebig Extracts began to appear on the market. To overcome this problem the Liebig Extract of Meat Company registered the trade mark LEMCO, from its initials. Whilst sales of LEMCO and its by product Corned Beef continued to rise, the Company expanded its product range. Another meat extract, OXO was developed for English taste which preferred its high salt, low fat piquant flavour. It was this product which formed the penny OXO cube, a cheap and convenient form of nourishment. The commencement of the First World War in 1914 severed all links with Belgium and the Liebig marketing company Oxo Limited was formed in London that same year to sell products in the UK. In 1924 Oxo Limited formed a Medical Division to sell glandular products to doctors under the trade name OXOID. About this time, LAB-LEMCO was developed for use in culture media. It was formulated from pale- coloured, low fat meat extracts which were more appropriate for the growth of micro-organisms. This was also the period when Liebig-Oxo increased investigation into enzymic- and acid-hydrolysis of meat and vegetable proteins to increase flavour and amino-nitrogen content of OXO. This work would eventually lead to the familiar peptones, such as Bacteriological Peptone L37. The Second World War in 1939 presented new challenges and opportunities for change. The formation of the Emergency Pathology Service (EPS) to combat epidemics and the threat of biological warfare, meant that bacteriological investigations increased greatly. The development of penicillin in the 1940s gave further impetus to this activity. The EPS was transformed into the Public Health Laboratory Service and penicillin was followed by many other antibiotics. The Medical Division of Oxo Ltd., began to turn its attention to this rapidly growing market where infectious disease diagnosis and the industrial production of allied biologicals were of increasing importance. When, in 1957, it was decided to stop sales of pharmaceutical products, the replacement products (Oxoid Culture Media) were already being developed. Experience in the War had shown the value of dehydrated media and it was decided that this would be the main activity of the Oxoid Division. So successful was this decision that in 1965, Oxoid Limited was created as a separate subsidiary company of Liebig Extract of Meat Company. In 1968 Liebig Extract of Meat Company merged with Brooke Bond Limited. The merged company was given the name Brooke-Bond Oxo and trade in culture media continued under Oxoid Limited. In 1984 Brooke-Bond Oxo was purchased by Unilever Plc and for the first time in its history Oxoid was separated from Oxo. This prepared the way for all Unilever’s medical products companies to be relaunched under a single international corporate identity, UNIPATH. Finally, in 1996 Unilever decided to concentrate more on its core businesses and as a result Oxoid became an independent company for the first time in its history. During the entire period of the Company’s development outlined above the science of bacteriology was itself evolving with considerable speed. Early observers of microscopic life forms including Needham (1745) had recognised the need for the preparation of suitable nutrient fluids for their growth but there was a lack of uniformity in the methods followed. The study of nutrient media possessing more exact composition was initiated by Pasteur in 1860. Cohn developed this work and published the formula for his ‘normal bacterial liquid’ in 1870.
Recommended publications
  • Produktkatalog 2015/2016
    Produktkatalog 2015/2016 BD Life Sciences Diagnostic Systems Deutschland . Österreich . Schweiz BD stellt sich vor BD Lifeweltweit Sciences – BD – LifeBD MedicalSciences – BD Medical BD – weltweit BD Life Sciences – Biosciences BD Life Sciences – Diagnostic Systems BD, eines der führenden Medizintech- Biosciences bedient den gesamten Diagnostic Systems ist Ihr Experte und nologie-Unternehmen, hat es sich zur Bereich der biologischen und medizi- erfahrener Partner für die klinische Aufgabe gemacht, in Zusammenar- nischen Forschung und bietet die und industrielle mikrobiologische Diag- beit mit seinen Kunden und Partnern größte Auswahl an innovativen Gerä- nostik. den gegenwärtigen und zukünftigen ten und Reagenzien für die zelluläre Umfassende Konzepte und daran ge- Herausforderungen bei der Gesund- Analyse an. knüpfte Diagnostika, Softwarelösun- heitsversorgung von Menschen auf Ein breites Spektrum an Analyzern gen und Dienstleistungen führen zu der ganzen Welt zu begegnen. und Sortern für die Durchflusszyto- gesteigerter Effizienz im Labor und Mit innovativen Lösungen optimiert metrie, verbunden mit kompetenter zu schnelleren verwertbaren Ergeb- BD die Arzneimittelverabreichung, Beratung und Service, ermöglichen nissen. verbessert die Diagnose von Infek- die passgenaue Lösung für Ihr Labor. Unser klinischer Fokus liegt in der Prä- tionskrankheiten und Krebs, unter- Unser Produktangebot und unsere vention und Diagnose von Infektions- stützt die Behandlung von Diabetes Kompetenz machen uns zum interes- krankheiten sowie des Zervixkarzinoms. und bringt die Zellforschung voran. santen Partner für Forschungs- und Für den klinischen Bereich bietet Diag- Rund 30.000 BD-Mitarbeiterinnen Routinelabors, für die Industrie sowie nostic Sytems integrierte Lösungen und Mitarbeiter in 50 Ländern setzen für die wachsende Zahl von bio- und auf den Gebieten Tuberkulose, Sep- sich dafür ein, unser Unternehmens- gentechnologischen Einrichtungen.
    [Show full text]
  • Survival of Bacteria in Pellets, Tablets and Capsules
    S u r v iv a l o f B a c t e r ia in P e l l e t s , T a b l e t s a n d C a p s u l e s By M a r ia K o u im t z i T h e s is p r e s e n t e d f o r t h e d e g r e e o f D o c t o r o f P h il o s o p h y IN THE F a c u l t y o f M e d i c i n e o f THE U n iv e r s it y o f L o n d o n S eptem ber 1999 T he School of Pharm acy U niversity of London ProQuest Number: 10104248 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest 10104248 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 A b s t r a c t The survival of probiotic and model organisms in pellets, tablets and capsules was investigated in an attempt to formulate stable solid oral dosage forms, containing probiotic bacteria.
    [Show full text]
  • XL Agar Base • XLD Agar
    XL Agar Base • XLD Agar clinical evaluations have supported the claim for the relatively Intended Use high efficiency of XLD Agar in the primary isolation ofShigella XL (Xylose Lysine) Agar Base is used for the isolation and and Salmonella.5-9 differentiation of enteric pathogens and, when supplemented with appropriate additives, as a base for selective enteric media. XLD Agar is a selective and differential medium used for the isolation and differentiation of enteric pathogens from clinical XLD Agar is the complete Xylose Lysine Desoxycholate Agar, specimens.10-12 The value of XLD Agar in the clinical laboratory a moderately selective medium recommended for isolation and is that the medium is more supportive of fastidious enteric organ- differentiation of enteric pathogens, especially Shigella species. isms such as Shigella.12 XLD Agar is also recommended for the XLD Agar meets United States Pharmacopeia (USP), European testing of food, dairy products and water in various industrial Pharmacopoeia (EP) and Japanese Pharmacopoeia (JP)1-3 standard test methods.13-17 General Chapter <62> of the USP performance specifications, where applicable. describes the test method for the isolation of Salmonella from nonsterile pharmaceutical products using XLD Agar as the solid Summary and Explanation culture medium.1 A wide variety of media have been developed to aid in the selective isolation and differentiation of enteric pathogens. Due Principles of the Procedure to the large numbers of different microbial species and strains Xylose is incorporated into the medium because it is fermented with varying nutritional requirements and chemical resistance by practically all enterics except for the shigellae.
    [Show full text]
  • OSPE Renal Micro AA
    MICROBIOLOGY PRACTICAL TEAMWORK 437 URINARY TRACT INFECTION Objectives: 1- Know the important steps in specimen collection and transport to the lab. 2-How to process urine Specimens in the lab. – Urine microbiological and biochemical analysis. – Organisms culture and identification. – Antibiotic susceptibility testing. – Results interoperation. 3- Know the clinically important etiological Organisms associated with UTI, their identification and susceptibility testing. Done by : ABEER ALABDULJABBAR NOURA ALOTHAIM OMAR ALSUHAIBANI Important aspects of Microbiologic Examination of UTI SPECIMEN COLLECTION : -Urine collection SPECIMEN PROCESSING : -Urine analysis -Urine culture -Interpretation of microbiology -laboratory result 1- SPECIMEN COLLECTION Type of specimens Midstream urine (MSU): best for adult The urine collected in a wide mouthed container from patients a mid stream specimen is the most ideal for processing Female patients pass urine with a labia separated and mid stream sample is collected Adhesive bag best for child Suprapubic aspiration Catheter sample: (used with elderly) Urine specimens for laboratory investigations can be collected from catheterized patients as shown (left). The second port is for putting fluids into the bladder (right). Urine from the drainage bag should not be tested because it may have been standing for several hours. TRANSPORT MEDIA -Sterile urine container -Dip slide (one side is CLED media and the other is MacConkey agar or blood agar) 2- SPECIMEN PROCESSING B-Culture and C-Antimicrobial A-Urine analysis identification Susceptibility D-Results (ID) testing interpretation • Microbiological Disk diffusion Culture media test Macroscopic Urine inoculation and E test Microscopic reading of culture Biochemical Identification of cultured organisms A-Urine analysis v Biochemical : Biochemical Urine Examination (Dip stick) Testing for UTI : Midstream clean catch with dipstick analysis Dipstick results may be affected by medications/dyes, i.e.
    [Show full text]
  • British National Formulary Google Books
    British National Formulary Google Books foundWeekdays and seditionItalianate, Roosevelt Nichols reinvolveforbore some film andimperialisms? extrudes ringings. Is Aleks niminy-piminy when Torrence loiter hoarily? How unrepented is Dean when Nature of Medicinal Herbs Herbal Formulary Herbal Remedies I II and Herbal Therapeutics. Emil Blonsky is for former special-ops commando with the British Royal Marines on pay to. The script is a political science and mental health and cpzes misleading report, xml parser was well informed by. British National Formulary Bnf Google Books. And social care professionals in the UK from the App Store and Google Play. Prescription drug buy in Canada a review but the. How fabulous I reference the British National Formulary BNFBNFC in APA 6th style. Use one called Google wwwgooglecouk or wwwgooglecom but customer are. Take into determining a place online or percentages were fast, die jeden neugierig machen. Infections the permit Book 2010 the British National Formulary for Children. Main page thumbnails provide a place of google books. Chlorpromazine equivalents and percentage of British National Formulary maximum. Wherever i can j, a variety of a radical change with paediatric formulary. ABC said always report was issued in November by the National Center for. My personal libraries though there is not be displayed if possible, legal according to your response efforts are not put to. Contributors Joint Formulary Committee Great Britain British Medical. Lsl list does list. New york state university wexner medical bloopers page view, google will help they cover patented medicine, press enter a false evidence is a tech reviews section. British National Formulary Dinesh Mehta Google Books.
    [Show full text]
  • Product List 2006
    94474 Product COVER 5/12/05 6:09 pm Page 1 [email protected] Данный документ является собственностью компании "СИМАС" www.simas.ru Product List 2006 т.ф. (495) 980-29-37, 781-21-58, 319-22-78, 311-22-09 Oxoid Price List 2006 International Orders UK Orders International Customer Services UK Customer Services Oxoid Limited Oxoid Limited Wade Road Wade Road Basingstoke Basingstoke Hampshire RG24 8PW Hampshire RG24 8PW UK Telephone: 01256 816566 Telephone: +44 (0) 1256 841144 Facsimile: 01256 334994 Facsimile: +44 (0) 1256 463388 e-mail: [email protected] e-mail: [email protected] Web: www.oxoid.com Web: www.oxoid.com Technical Support Helpline Technical Support Helpline Telephone: 01256 694281 Telephone: +44 (0) 1256 694287 Facsimile: 01256 329728 Facsimile: +44 (0) 1256 329728 e-mail: [email protected] e-mail: [email protected] For details of your local Oxoid distributor Telephone: +44 (0) 1256 694347 Facsimile: +44 (0) 1256 329728 www.oxoid.com ForFor.b:w9cee(e-bb@+5.b@b-wi,b9b@b-wlP Conditions of Sm9@Fb@@ndibil: [email protected] ec’ F,w.oph.:Support +5.b:xoi. +ee(e-bb@ 94474 Product Text 3/12/05 9:31 am Page 1 [email protected] Данный документ является собственностью компании "СИМАС" www.simas.ru Contents PAGE PAGE ❐ Important Information 2 ❐ AST 25 ❐ Products by Organism 3 Aura System 25 ❐ Worldwide Distributors 6 Disc Dispensers 25 Discs 28 ❐ Prepared Media 21 Diagnostic Discs 28 Dip Slides 21 ❐ Ready Bags 22 ID Biochemical Tests 29 Prepared Media 22 Microbact 29 Biochemical Reagents 28 OBIS Kits 28 ❐ Culture Media 9 Touch Sticks
    [Show full text]
  • Determination of Meropenem Stability Over 8 Hours in the Marketed Brands
    Study of this antibiotic to have maximal therapeutic outcome. a testing concentration of 5 μg/ml. 50ml were transferred Meropenem stability after reconstitution has been shown to into a 50ml syringe pump connected to a 150cm extension be affected by the concentration of the resultant solution, the tube and an IV catheter to exactly mimic the conditions in Determination of Meropenem Stability ambient temperature, and the time after reconstitution5,6,7. which Meropenem is used in the hospital. The rate of IV The European Pharmacopeia (EP), British Pharmacopeia infusion was set at 6ml/hr. Samples were withdrawn from (BP) and the United States Pharmacopeia (USP) the IV catheter at the following time intervals: T0, T0.5, Over 8 Hours in the Marketed Brands recommend the UV absorbance assay for the identification T1, T2, T3, T4, T5, T6, T7, & T8. of Meropenem2,8,9. In the present study, we have developed a UV-spectrophotometric protocol for the determination UV Spectroscopy of Meropenem stability after reconstitution with Normal of Meropenem stability after reconstitution with Normal Withdrawn samples were scanned for absorbances at Saline at room temperature. We have also compared the Saline at room temperature. We have also compared the wavelengths ranging from 190 to 400nm at a reading stability of different Meropenem brands present in the stability of different Meropenem brands present in the interval of 1nm with special focus at the 200nm wavelength Lebanese market as compared to the Originator product Lebanese market together with the percentage of the for stability testing because the latter wavelength is Meronem®(Astrazeneca™). During the 3 hours interval, Active Ingredient as compared to the Originator product considered as a reference for stability/purity testing of the 10 only Meronem® & Aropem® have been stable, where as Meronem® (Astrazeneca™).
    [Show full text]
  • Salmonella Enterica and the Specific Interaction with Lactuca Sativa
    Quantitative detection of Salmonella enterica and the specific interaction with Lactuca sativa Michel M. Klerks 2007 Promotor: Prof. Dr. Ir. A. H. C. van Bruggen Hoogleraar in de Biologische Landbouwsystemen Wageningen Universiteit Co-promotor: Dr. Ir. C. Zijlstra Clusterleider Moleculaire Phytopathologie Wageningen UR, Plant Research International BV Promotie commissie: Prof. Dr. Ir. P. J. G. M. de Wit, Wageningen Universiteit Prof. Dr. Ir. M. H. Zwietering, Wageningen Universiteit Prof. Dr. Ir. J. D. van Elsas, Rijksuniversiteit Groningen Dr. Ir. H.J. M. Aarts, RIKILT, Instituut voor voedselveiligheid Dit onderzoek is uitgevoerd binnen de C.T. de Wit Onderzoekschool ‘Productie Ecologie en Beheer van Natuurlijke Hulpbronnen’ Quantitative detection of Salmonella enterica and the specific interaction with Lactuca sativa Michel M. Klerks Proefschrift ter verkrijging van de graad van doctor op gezag van de rector magnificus van Wageningen Universiteit Prof. Dr. M. J. Kropff, in het openbaar te verdedigen op woensdag 20 juni 2007 des namiddags te 13.30 uur in de Aula Michel M. Klerks (2007) Quantitative detection of Salmonella enterica and the specific interaction with Lactuca sativa. Doctoral thesis - Biological Farming Systems Group - Wageningen University - The Netherlands. Subject headings: Salmonella enterica, Escherichia coli, detection, lettuce, plant response, pathogenicity, route of infection ISBN: 978-90-8504-674-5 Contents Abstract Chapter 1 General introduction 9 Chapter 2 Comparison of real-time PCR methods for detection of 39
    [Show full text]
  • Laboratory Diagnosis of Shigella and Salmonella Infections *
    Bull. Org. mond. Sante) 1959, 21, Bull. Wid Hlth Org. 247-277 Laboratory Diagnosis of Shigella and Salmonella Infections * E. HORMAECHE, M.D.' & C. A. PELUFFO, M.D.2 In recent years a great deal of work has been We are aware that experienced bacteriologists devoted to the study of enteric diseases and, in will prefer some of the methods they are using to consequence, many methods have been developed the ones we recommend. This study is not in- for the isolation of their most common agents, tended for them, however, but rather as a guide to Shigella, Salmonella and some pathogenic Esche- people who are just starting work on enteric diseases richia, while at the same time new tests have been diagnosis. For more detailed information, we devised to differentiate the " groups " of the Entero- recommend the books of Kauffmann (1954) and bacteriaceae family, so that the beginner, especially, Edwards & Ewing (1955), of which we have made will be faced with the difficulty of selecting from ample use. among them those to be used. Investigation of enteric pathogens will sometimes Each author has his preferences according to his be the ultimate purpose, as for the public health own experience, and it is regrettable that up to now officer, who is primarily interested in finding them no serious effort has been made to standardize for the potential danger they represent to the com- techniques, which would save a lot of time and dis- munity. In clinical medicine, however, the role couraging failures for the bacteriologist unex- played by the bacteriologist does not end there.
    [Show full text]
  • Testing Inhaled Generics
    Generic Bioequivalence Testing Inhaled Generics By Mark Copley New product-specific FDA guidance and USP monographs support at Copley the development of popular inhaled products. This article reviews their Scientific value in the rapidly growing generic sector Central to the development of a monographs for inhaled products, Ensuring Efficiency new generic product is the need to which closely detail appropriate demonstrate bioequivalence (BE) testing for off-patent active The number of generic in order to confirm pharmaceutical ingredients. The FDA and USP are submissions to the FDA has equivalence to the reference labelled discrete, independent bodies, so risen exponentially over the last drug (RLD) being replicated. Such there is no obligation to adhere decade or so, with substantial evidence is typically supplied in the to USP monographs as part of a expansion in the generic sector form of in vitro and in vivo test data. submission process, even though – in particular in India, where In vitro tests are usually the first step it is common practice to do so to annual growth rates remain in and preferable to the manufacturer reduce the risk of inadequate excess of 25% (5). A stated aim from the perspective of ease, cost data provision. of publishing product-specific and speed, but choosing a testing guidance is to streamline the strategy that yields suitable data is Monographs describe the tests process of providing support also important. required to “ensure the substance with the design of BE studies, as a is of the appropriate strength, way of improving efficiency (1). For certain widely used pharma quality and purity” (3), and provide Furthermore, better quality products, the FDA has released a standard that can be used by submissions have the potential product-specific guidance to the FDA to assess compliance to reduce the burden of regulatory support the generic submission and by manufacturers to guide assessment without increasing risk.
    [Show full text]
  • Downloads/Advisorycommit Analgesics
    * DD&D Jan 2014 Covers.qxp_DDT Cover/Back April 2006.qx 1/3/14 4:59 PM Page 2 January 2014 Vol 14 No 1 www.drug-dev.com IN THIS ISSUE INTERVIEW WITH EMD MILLIPORE’S HEAD OF PORTFOLIO DEVELOPMENT STEFFEN DENZINGER Second Quadrant 22 Marshall Crew, PhD Device Engineering 26 Chris Hurlstone Deterring Opiod Abuse 34 Cindy H. Dubin Lyophilization Packaging 42 Thomas Otto The science & business of drug development in specialty pharma, biotechnology, and drug delivery Drug Delivery Innovation 66 Amy Heintz, PhD Derek Geoff Carr, PhD Justin M. Hennecke Developing & Validating an Efficient Wright, PhD Six Reasons Why Data Method to Determine Delivering the Next the Affordable Residuals of Generation in Glass Management 68 Care Act May Be Hormone Products Prefillable Syringes a Bad-Tasting by LC-MS After Martin Magazzolo Medicine That Cleaning Equipment Could Heal Our Industry 2-4 DDD January 2014 front pages.qxp_DDT Frntmttr apr06 06.2-4.qx 1/3/14 5:00 PM Page 2 2-4 DDD January 2014 front pages.qxp_DDT Frntmttr apr06 06.2-4.qx 1/3/14 5:00 PM Page 3 2-4 DDD January 2014 front pages.qxp_DDT Frntmttr apr06 06.2-4.qx 1/3/14 5:00 PM Page 4 January 2014 Vol 14 No 1 PUBLISHER/PRESIDENT Ralph Vitaro [email protected] EXECUTIVE EDITORIAL DIRECTOR Dan Marino, MSc [email protected] CREATIVE DIRECTOR Shalamar Q. Eagel CONTROLLER Debbie Carrillo CONTRIBUTING EDITORS Cindy H. Dubin John A. Bermingham Josef Bossart, PhD Katheryn Symank TECHNICAL OPERATIONS Mark Newland EDITORIAL SUPPORT Nicholas D.
    [Show full text]
  • Medios En Placas Preparadas
    Medios de cultivo Hemoderivados, Medios en placas preparadas Sheep Blood in Alsevers Solution Iso-Sensitest Agar (Placa profunda) 25 mL SR0053B 10 x 90 mm PO0779A Iso-Sensitest Agar with Chocolated Horse Blood Sheep Blood Defibrinated 10 x 90 mm PB0147A 25 mL SR0051B Iso-Sensitest Agar with Horse Blood 10 x 90 mm PB0146A Medios en placas preparadas Iso-Sensitest Agar with Horse Blood and 20mg/L NAD 10 x 90 mm PB0378A Agares sangre Iso-Sensitest Agar con sangre de caballo lisada Blood Agar Base No. 2 with Horse Blood 10 x 90 mm PB0145A 10 x 90 mm PB0114A Iso-Sensitest Agar with Sheep Blood Blood Agar Base No. 2 with Sheep Blood 10 x 90 mm PB5003A 10 x 90 mm PB0115A Mueller Hinton Agar Columbia Agar with Horse Blood 10 x 90 mm PO5007A 10 x 90 mm PB0122A Mueller-Hinton Agar with 2% Salt Columbia Agar with Sheep Blood 10 x 90 mm PO0799A^ 10 x 90 mm PB5008A 10 x 90 mm PO5139A+ Columbia Agar with Sheep Blood PLUS Mueller-Hinton Agar 10 x 90 mm PB0123A*^ 10 x 90 mm PO0152A^ 10 x 90 mm PB5039A+ 10x120mm PO1191S Columbia Agar with Chocolated Horse Blood Mueller-Hinton Agar with 5% Sheep Blood 10 x 90 mm PB0124A 10 x 90 mm PB0431A^ 10 x 90 mm PB5007A+ Agares generales para anaerobios Mueller Hinton Agar with Horse Blood Thermo ScientificTM A.R.I.A.TM with Horse Blood 10 x 90 mm PB1229A^ 10 x 90 mm PB1243A 10 x 90 mm PB5303A+ A.R.I.A.
    [Show full text]